A5051475590- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Single-cell and spatial transcriptomics
- Genomics and Rare Diseases
- Epigenetics and DNA Methylation
- Molecular Biology Techniques and Applications
- Genetic factors in colorectal cancer
Memorial Sloan Kettering Cancer Center
2022-2024
Kettering University
2023-2024
Abstract Despite insights gained by bulk DNA sequencing of cancer it remains challenging to resolve the admixture normal and tumor cells, and/or distinct subclones; high-throughput single-cell circumvents these brings genomic studies higher resolution. However, its application has been limited liquid tumors or a small batch solid tumors, mainly because lack scalable workflow process samples. Here we optimize highly automated nuclei extraction that achieves fast reliable targeted...
Abstract Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic relapse site. Subclonal...
Although the pancreatic cancer genome has been described, it not explored with respect to stages of diagnosis or treatment bottlenecks. We now describe and quantify genomic features PDAC in context evolutionary metrics doing so have identified a novel prognostic biomarker.
Abstract Late-stage disease consists of more than half pancreatic ductal adenocarcinoma (PDAC) at diagnosis, but most samples have low tumor purity that limits bulk DNA sequencing. Additionally, as clonal evolution happens single-cell level, sequencing misses many insights such subclones, colocalization events etc. Thus, we aim to refine our understanding PDAC and heterogeneity with Previously developed a scalable, high-throughput single-nucleus DNA-seq (snDNA-seq) method...
Abstract Numerous next-generation sequencing studies have provided an overview pancreatic ductal adenocarcinoma (PDAC)’s genomic evolution. But how its genome evolves through treatment and metastasis has not been extensively studied due to lack of samples technical limitation bulk on low-tumor purity samples. Herein we applied targeted single-nucleus DNA (snDNA-seq) a cohort 18 patients, each with >= 2 multiregional/longitudinal samples, totaling 65 These included 5 early-stage...
Multiple large-scale tumor genomic profiling efforts have been undertaken in osteosarcoma, however, little is known about the spatial and temporal intratumor heterogeneity how it may drive treatment resistance. We performed whole-genome sequencing of 37 samples from eight patients with relapsed or refractory osteosarcoma. Each patient had at least one sample a primary site metastatic relapse site. identified subclonal copy number alterations all but patient. observed that five patients,...
Abstract Despite insights gained by bulk DNA sequencing of cancer it remains challenging to resolve the admixture normal and tumor cells, and/or distinct subclones; high throughput single-cell circumvents these brings genomic studies higher resolution. However, its application has been limited liquid tumors or a small batch solid tumors, mainly because lack scalable workflow process samples. Here we optimized highly automated nuclei extraction that achieved fast reliable targeted...
Abstract Despite insights gained by bulk DNA sequencing of cancer it remains challenging to resolve the admixture normal and tumor cells, and/or distinct subclones; high throughput single-cell circumvents these brings genomic studies higher resolution. However, its application has been limited liquid tumors or a small batch solid tumors, mainly because lack scalable workflow process samples. Here we optimized highly automated nuclei extraction that achieved fast reliable targeted...
<div>Abstract<p>Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic...
<p>Supplementary Figures</p>
<div>Abstract<p>Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial temporal intratumor heterogeneity could also play a role promoting tumor growth treatment resistance. We conducted longitudinal whole-genome sequencing 37 samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample primary site metastatic...
<p>Supplementary Figures</p>